DC1s-CTL Cellular Therapy for Renal Cell Carcinoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02787915|
Recruitment Status : Unknown
Verified May 2016 by Junnian Zheng, Xuzhou Medical University.
Recruitment status was: Not yet recruiting
First Posted : June 1, 2016
Last Update Posted : June 2, 2016
|Condition or disease||Intervention/treatment||Phase|
|Renal Cell Carcinoma||Biological: DC1-CTL||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||DC1s-CTL Cell Therapy to Treat Patients With Renal Cell Carcinoma After Radical Resection|
|Study Start Date :||September 2016|
|Estimated Primary Completion Date :||August 2019|
|Estimated Study Completion Date :||August 2019|
Experimental: dendritic cell vaccine
DC1-CTL cellular therapy
Autologous cytotoxic of T lymphocytes (CTL) were induced by type-1 polarized dendritic cells (DC1) loaded with MAGE-3/MAGE-4/survivin/ her2 /COX-2 CTL epitope peptides .
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 24 weeks ]Our primary objective is to evaluate whether our cellular therapy regimen is safe.
- G250 mRNA figures [ Time Frame: 24 weeks ]
- T cell subsets figures [ Time Frame: 12 weeks ]
- Serum cytokine secretion figures [ Time Frame: 12 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02787915
|Contact: Junnian Zheng, MDfirstname.lastname@example.org|
|Contact: Huizhong Li, MMemail@example.com|
|Principal Investigator:||Junnian Zheng, MD||Xuzhou Medical University|